# A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease

> **NCT04269551** · PHASE1 · COMPLETED · sponsor: **Bioverativ, a Sanofi company** · enrollment: 12 (actual)

## Conditions studied

- Autoimmune Haemolytic Anaemia

## Interventions

- **DRUG:** BIVV020

## Key facts

- **NCT ID:** NCT04269551
- **Lead sponsor:** Bioverativ, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-15
- **Primary completion:** 2022-01-06
- **Final completion:** 2022-01-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04269551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04269551, "A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04269551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*